Marker Therapeutics, Inc. (MRKR) is a late-stage cancer therapeutics company specialized in the production of T cell-based immunotherapeutics for treating oncological issues. The company’s lead candidates are not much expensive to produce and have lesser toxicities.
The price of MRKR stock during the regular trading on February 18, 2022, was $0.41 with a decline of 9.19%. At last check in the aftermarket, the stock surged by 10.8%.
MRKR: Events and Happenings
On February 18, 2022, MRKR announced filing the report of unscheduled material events or corporate events with the SEC.
MRKR: CEO Comments
On February 17, 2022, MRKR updated about its clinical programs, production procedure, and pipeline. Speaking at the occasion, MRKR’s CEO Peter L. Hoang stated that the company’s T cell production procedure is designed to manufacture an increased potency product with enhanced antigen specificity. He further added that the company is planning to expand its pipeline to pancreatic cancer patients.
On January 19, 2022, MRKR reported about the grant of Orphan Drug Designation by the FDA’s Office of Orphan Products Development to MT-601. On November 18, 2021, MRKR announced that the data from Phase 1 clinical trials of MultiTAA-specific T cells were selected for presentation at the American Society of Hematology Annual Meeting 2021 held on December 11-14, 2021.
MRKR: Key Financials
On November 10, 2021, MRKR released its financial results for the third quarter ended September 30, 2021. Some of the key updates are discussed below.
Revenue
No revenue was reported in Q3 2021 as in the same quarter of 2020.
EPS
Basic and diluted net loss per share in the third quarter of 2021 was $12.4 million or $0.15 as compared to net income of $7.37 million or $0.16 in the same period of 2020. The company observed an increase in EPS over the period of the year. Also, the company missed the analysts’ estimates by -$0.02.
On September 7, 2021, MRKR reported about its Executive management’s presence at the following three investor conferences.
- C. Wainwright Virtual Annual Global Investment Conference on September 13,
- Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit on September 22, and
- Cantor Fitzgerald Virtual Global Healthcare Conference on September 27, 2021.
Conclusion
MRKR stock is 84% down the past year as the companies faced an economic crisis in the pandemic. The current aftermarket stock incline is the result of a recent filing with the SEC. As the company is gearing for its earnings release date, the analysts are estimating EPS to be -$0.13.
